Hritz, I <br/><br/>
Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective COX-2 users.  [electronic resource] 

 -  International journal of immunopathology and pharmacology   
 - 75-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0394-6320 
<br/><br/><label>Standard No.: </label>10.1177/039463200501800109  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Apoptosis--drug effects<br/>Cell Count<br/>Cell Proliferation--drug effects<br/>Cyclooxygenase 2<br/>Cyclooxygenase 2 Inhibitors<br/>Cyclooxygenase Inhibitors--adverse effects<br/>DNA Damage--drug effects<br/>Double-Blind Method<br/>Enzyme Inhibitors--therapeutic use<br/>Female<br/>Gastric Mucosa--pathology<br/>Genes, erbB-1--genetics<br/>Genes, p53--genetics<br/>Humans<br/>Immunohistochemistry<br/>In Situ Nick-End Labeling<br/>Male<br/>Membrane Proteins<br/>Middle Aged<br/>Proliferating Cell Nuclear Antigen--metabolism<br/>Prostaglandin-Endoperoxide Synthases--metabolism<br/>Proton Pump Inhibitors<br/>Stomach Ulcer--chemically induced